

This article was downloaded by: [Univ di Roma Tor Vergata]

On: 03 June 2015, At: 00:03

Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK

CellCycle

Volume 14-Issue 4-February 15, 2015



Editor in Chief
Alf Hagström MD, PhD
alf.hagstrom@ki.se

Editorial Board

Adrian Alnemri	Michael Karin
David Baltimore	Michael Mann
Richard D. Blumberg	Michael Orian
Robert C. Branton	Richard A. Young
John R. Caspar	David R. Greenblatt
Michael S. Cohen	David G. Klapper
Michael J. Cooper	David L. Klapper
Michael J. Curran	David M. Livingston
Michael E. DeLoraine	David M. Livingston
Michael E. DeLoraine	David M. Livingston
Michael E. DeLoraine	David M. Livingston
Michael E. DeLoraine	David M. Livingston



Cell Cycle

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/kccy20>

T538 phosphorylation, Pin-ing p63-Itch stability

Akram Alian^a & Rami I Aqeilan^{bc}

^a Faculty of Biology; Technion - Israel Institute of Technology; Haifa, Israel

^b The Lautenberg Center for General and Tumor Immunology; Department of Immunology and Cancer Research-IMRIC; Faculty of Medicine; Hebrew University of Jerusalem; Jerusalem, Israel

^c Human Cancer Genetics Program; Ohio State University Comprehensive Cancer Center; Columbus, OH USA

Accepted author version posted online: 15 Jan 2015.



[Click for updates](#)

To cite this article: Akram Alian & Rami I Aqeilan (2015) T538 phosphorylation, Pin-ing p63-Itch stability, Cell Cycle, 14:4, 469-470

To link to this article: <http://dx.doi.org/10.1080/15384101.2015.1006553>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

T538 phosphorylation, Pin-ing p63-Itch stability

Comment on: Melino S, et al. p63 threonine phosphorylation signals the interaction with the WW domain of the E3 ligase Itch. *Cell Cycle* 2014; 13(20):3207-17; <http://dx.doi.org/10.4161/15384101.2014.951285>

Akram Alian^{1,*} and Rami I Aqeilan^{2,3} ¹Faculty of Biology; Technion – Israel Institute of Technology; Haifa, Israel; ²The Lautenberg Center for General and Tumor Immunology; Department of Immunology and Cancer Research-IMRIC; Faculty of Medicine; Hebrew University of Jerusalem; Jerusalem, Israel; ³Human Cancer Genetics Program; Ohio State University Comprehensive Cancer Center; Columbus, OH USA; *Correspondence to: Akram Alian; Email: alian@tx.technion.ac.il; Rami I Aqeilan; Email: ramiaq@mail.huji.ac.il; <http://dx.doi.org/10.1080/15384101.2015.1006553>

p63 is known as a regulator of cell cycle and apoptosis in response to genotoxic insults and for its function in regulation of epithelial morphogenesis. Melino and colleagues now demonstrate that phosphorylation of a conserved threonine (T538) regulates p63 stability and degradation mediated by WW domain containing proteins, Itch and Pin1.

WW domains are protein modules that mediate protein-protein interactions through

recognition of proline-rich peptide motifs and phosphorylated serine/threonine-proline (S/T) P sites.¹ p63, a member of the p53 family of transcription factors and known to play a crucial role in regulating transcription of genes with distinct biological functions in regulating epithelium development and differentiation, metastasis and chemosensitivity,^{2,3} contains a (T/S)PPPXY domain which equates to a class IV WW target domain, (T/S)P, followed by a class

I WW domain target, PPXY. Indeed p63 is a known target of Class I WW domains interacting with Itch, an ubiquitin E3 ligase, which via its WW2 domain mediates the proteasomal degradation of p63.^{4,5} More recently, it has been shown that Pin1, a prolyl-peptidyl *cis/trans* isomerase protein which targets Class IV WW domains, modulates p63 protein stability by inhibiting p63 proteasomal degradation.⁶ In their latest study, Melino and colleagues⁷ elucidate aspects of p63 stability mediated by the WW domain-containing proteins Itch and Pin1, proposing a twofold regulation mechanism: whereas phosphorylation of threonine (T538) within the (T/S)PPPXY motif of p63 increases its binding affinity to the Itch WW domain, a post phosphorylation *cis/trans* switch catalyzed by Pin1 prolyl-isomerase regulates the final outcome of this interaction.⁷ This further extends on previous observations that E3 ligases prefer the *trans* conformer (reviewed in⁸) showing that the more relaxed *trans* conformer is indeed favorable for Itch binding. This is likely a consequence of the favorable local structural and chemical complementarity with the WW binding trench (Fig. 1). To maintain steady states of p63 levels in the cell, Melino and colleagues⁷ proposed that the *cis/trans* equilibrium and consequent stability of the Itch-p63 interaction might be regulated by Pin1, which catalyzes the formation of the Itch-unfavorable *cis* conformation.

The twofold *post phosphorylation conformational switch* mechanism observed by Melino et al.⁷ is unlikely limited to the Itch-p63 interaction and could also be true for other WW domain interacting partners. Indeed, it has recently been shown that Pin1 directly binds to and stabilizes p63 inhibiting proteasomal degradation mediated by the E3 ligase WWP1.⁶ Pin1 specifically interacts with T538P and disrupts p63 α -WWP1 interaction.⁶




Figure 1. The local structural configuration of the *cis* isomer, with the phosphate group twisted away from favorable interactions with the WW domain to favor self-interactions with the peptide's own amides, restrains Itch binding leading to p63 stabilization against subsequent ubiquitylation. The *trans* conformation exposes the negatively charged phosphate group for stabilizing interactions with a conserved⁷ basic arginine complement within the WW domain.

Likewise, Pin1 binding to phosphorylated p53 or p73 family members has been shown to stabilize both proteins by inhibiting p53 binding to E3 ligase MDM2 or increasing p73 acetylation by p300 (reviewed in ⁸). This study also highlights the essentiality of tightly regulating p(S/T)P motifs involved in pivoting the disastrous switch between normal and pathologic cellular signaling. Considering that the human proteome is highly enriched with (S/T)P motifs,⁹ it is fair to presume that Pin1, implicated in regulation of cell proliferation, transformation, and tumor growth, interacts with many other phospho-(S/T)P motif containing proteins in order to modulate their function.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The authors are grateful to Dr. Ailie Marx for critical reading of the manuscript.

Funding

The Aqeilan lab is supported, in part, by funds from the Israel Science Foundation (ISF 12-542).

References

1. Salah Z, et al. *Front Biosci* 2012; 17:331-48; PMID:22201747; <http://dx.doi.org/10.2741/3930>
2. Murray-Zmijewski F, et al. *Cell Death Differ* 2006; 13:962-72; PMID:16601753; <http://dx.doi.org/10.1038/sj.cdd.4401914>
3. Su X, et al. *Nat Rev Cancer* 2013; 13:136-43; PMID:23344544; <http://dx.doi.org/10.1038/nrc3446>
4. Rossi M, et al. *Proc Natl Acad Sci U S A* 2006; 103:12753-8; PMID:16908849; <http://dx.doi.org/10.1073/pnas.0603449103>
5. Rossi M, et al. *Cell Cycle* 2006; 5:1816-22; PMID:16861923; <http://dx.doi.org/10.4161/cc.5.16.2861>
6. Li C, et al. *Cell death & disease* 2013; 4:e943; PMID:24309930; <http://dx.doi.org/10.1038/cddis.2013.468>
7. Melino S, et al. *Cell Cycle* 2014; 13:3207-17; PMID:25485500; <http://dx.doi.org/10.4161/15384101.2014.951285>
8. Lu KP, Zhou XZ. *Nat Rev Mol Cell Biol* 2007; 8:904-16; PMID:17878917; <http://dx.doi.org/10.1038/nrm2261>
9. Abu-Odeh M, et al. *J Biol Chem* 2014; 289:8865-80; PMID:24550385; <http://dx.doi.org/10.1074/jbc.M113.506790>